多西他赛加表柔比星用于中晚期乳腺癌新辅助化疗的临床
研究
贺新爱;吕晶晶;邹明雷
【期刊名称】《医学理论与实践》 【年(卷),期】2014(000)015
【摘要】Objective :To observe the effects and adverse reactions of Neoadjuvant Chemothempy (NCT ) with Docetax-el plus Epirubicin in patients with advanced breast cancer .Methods:40 patients with advanced breast cancer are treated in the department of breast surgery .All patients are treated with Docetaxel 75mg/m2 and Epirubicin 75mg/m2 intrave-nously guttae on 1d .It is going to evaluate the effects and adverse reactions after 3 to 5 periods which are 21 days .Re-sults :The overall response rate(ORR) was 87 .50% ,the complete response(CR) was 40 .00% ,and the partial response (PR) was 47
.50%
.The
major
adverse
reactions
were
alopecia(100 .00% ) ,leukopenia(92 .50% ) ,gastrointestinal reac-tions(60 .00% ) ,thrombocytopenia (47 .50% ) ,cardiac toxicity (27 .50% ) ,and stomatitis (17 .50% ) .Conclusion:It is high efficiency and well tolerated for patients with advanced breast cancer which Docetaxel plus Epirubicin is used to do the Neoadjuvant Chemothempy .It is worthy of clinical promotion .%目的：观察多西他赛联合表柔比星的新辅助化疗（NCT ）方案在中晚期乳腺癌治疗中的疗效及毒副反应。方法：选择我院
多西他赛加表柔比星用于中晚期乳腺癌新辅助化疗的临床研究
